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Neutralizing (nAbs) and high afﬁnity binding antibodies may be critical for an efﬁcacious HIV-1 vaccine.
We characterized virus-speciﬁc nAbs and binding antibody responses over 21 months in eight HIV-1
subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous
nAb titers of study exit plasma against study entry viruses were signiﬁcantly higher than contempora-
neous responses at study entry (p¼0.002) and exit (p¼0.01). NAb breadth and potencies against
subtype C viruses were signiﬁcantly higher than for subtype A (p¼0.03 and p¼0.01) or B viruses
(p¼0.03; p¼0.05) respectively. Gp41-IgG binding afﬁnity was higher than gp120-IgG (p¼0.0002).
IgG–FcgR1 afﬁnity was signiﬁcantly higher than FcgRIIIa (po0.005) at study entry and FcgRIIb
(po0.05) or FcgRIIIa (po0.005) at study exit. Evolving IgG binding suggests alteration of immune
function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease
progression.
& 2012 Elsevier Inc. All rights reserved.Introduction
In 2010 alone, there were an estimated 2.4–2.9 million new
HIV-1 infections worldwide with 70% of these new infections
occurring in sub-Saharan Africa (UNAIDS, 2011). This high HIV
incidence makes the development of a protective vaccine a global
public health priority. Such a vaccine will likely need to elicit
antiviral antibodies, similar to the successful vaccines against
other viral infections such as hepatitis B, measles, mumps and
polio that are thought to mediate their effects primarily through
antibody mechanisms (Plotkin, 2008). However, despite intense
efforts in the study of HIV envelope structure and immunogen
design, the development of an efﬁcacious vaccine able to induce
broadly effective antibody responses remains elusive.ll rights reserved.
Institute, Nelson R. Mandela
ate Bag X7, Congella, DurbanDuring natural HIV infection, only a subset of individuals, less
than 30%, develop broad, cross-neutralizing antibodies after many
years (Gray et al., 2011; Li et al., 2009; Sather et al., 2009; Simek
et al., 2009; Stamatatos et al., 2009). Such individuals have been
an important source of new neutralizing monoclonal antibodies
(nmAbs) against the HIV envelope that have enhanced our under-
standing of HIV pathogenesis, envelope structure and provided
clues for rational immunogen design (Pejchal et al., 2011; Walker
et al., 2010; Wu et al., 2010). However, clinical beneﬁt of anti-HIV
antibodies has not yet been deﬁnitively demonstrated. Given that
HIV-1C is the predominant circulating and most rapidly spreading
subtype worldwide (Esparza, 2005; Hemelaar et al., 2011),
screening, characterizing and understanding the types of nAbs
produced by HIV-1C-infected individuals; and deﬁning the poten-
cies and breadth of these nAbs may contribute to the design of the
next generation of envelope immunogens.
While only some people develop cross-neutralizing antibodies,
autologous nAbs (AnAbs) appear in almost all HIV-infected indivi-
duals usually within the ﬁrst year. A number of studies have shown
that contemporaneous viruses are less sensitive to AnAbs than
D. Archary et al. / Virology 433 (2012) 410–420 411earlier autologous viruses suggesting that viral evolution and escape
occurs rapidly and this remains a signiﬁcant obstacle to HIV vaccine
development (Delwart et al., 1997; Moore et al., 2009; Richman
et al., 2003; Rong et al., 2009; Wei et al., 2003). Several mechanisms
of viral escape have been documented; these include insertions and
deletions of amino acids, amino acid substitutions and shifting the
position of N-linked glycans in Env (Frost et al., 2005; Lynch et al.,
2011; Moore et al., 2009; Rong et al., 2009). Further understanding
of HIV antibody escape patterns and mechanisms may help to
inform better immunogen design to overcome Env diversity and
immune escape.
Although the major focus of the HIV vaccine ﬁeld is the develop-
ment of immunogens able to induce broadly neutralizing antibodies,
V1–V2 binding antibodies appear to have played some role against
HIV-1 acquisition in the RV144 vaccine trial (Haynes et al., 2012). The
role of binding or non-neutralizing antibodies in inhibiting virus
replication through an Fc (fragment crystallizable) receptor (FcR)-
dependent mechanism has been demonstrated (Peressin et al., 2011).
FcRs are part of the immunoglobulin (Ig) superfamily and bind to the
Fc portion of antibodies forming a bridge between the cell bearing the
target antigens and the effector cell (Nimmerjahn and Ravetch, 2007).
FcgRs have either an activating or inhibitory function with relative
IgG binding afﬁnities. FcgRI (high afﬁnity), FcgRIIa and FcgRIIIa
(medium–low afﬁnity)—all have activating functions; and FcgRIIb
has an inhibitory function (medium–low afﬁnity) (Forthal and Moog,
2009; Siberil et al., 2007). The effector cell subsequently mediates
virus killing through antibody-dependent cell mediated cytotoxicity
(ADCC) or through antibody-dependent cell-mediated viral inhibition
(ADCVI). Some studies have shown that the strength of binding
interaction between the Fc region of the antibody and the FcgRIIIa
and/or FcgRIIa potently increases ADCC activity and Fc binding
afﬁnity could be altered through deglycosylation or site-speciﬁc
mutagenesis, abrogating downstream ADCC (Jefferis, 2009; Lazar
et al., 2006; Richards et al., 2008; Shields et al., 2001). Thus Fc-
binding interaction may be crucial in improving the efﬁcacy of
antibodies (Lazar et al., 2006). These studies therefore provide a
rationale for assessing the binding afﬁnities of the IgG-Fc regions to
their cognate FcgRs as an indication of putative antiviral activity of
binding antibodies in vivo. Previously, ADCC activity was reported to
be signiﬁcantly higher in elite controllers compared to chronic
progressors (Lambotte et al., 2009). These data on HIV are consistent
with earlier studies suggesting a role for non-neutralizing antibodies
in viral control and disease attenuation (Alsmadi et al., 1997; Baum
et al., 1996). More recently, it was demonstrated that non-
neutralizing antibodies conferred protection, albeit limited, to maca-
ques against vaginal SHIV challenge (Burton et al., 2011). The binding
afﬁnities of IgGs to various HIV-1 antigens and to FcgRs have rarely
been studied together and no studies have reported on the char-
acterization of these antibodies in chronic HIV-1 subtype C infections.
In this study, we used standard high throughput neutralization
assays to evaluate the potency and breadth of neutralizing
activity in patient plasma and map potential Env targetsTable 1
Clinical description of study participants.
Patient
Identiﬁcation
Sex Age at
baseline
Viral load study
entry (copies/ml)
Viral load study
exit (copies/ml)
SK010 F 31 6480 345,000
SK035 F 31 5800 2950
SK036 M 32 5100 10,600
SK169 F 30 2210 2440
SK200 F 40 14,360 24,900
SK221 F 30 9740 23,700
SK233 F 22 11,800 18,900
SK312 F 59 3460 3630associated with nAb breadth. We proﬁled autologous and cross-
reactive (against a standard panel of 20 subtype A, B and C
viruses) nAb titers in eight chronically HIV-1C infected indivi-
duals with heterogeneous rates of disease progression. Envelope
genotypic characteristics (amino acid length and numbers of
potential N-linked glycosylation sites (PNGs) associated with
autologous nAb titers were investigated. Binding afﬁnities of total
immunoglobulins (IgGs) to HIV-1 antigens (gp41, gp120 and p24)
and FcgRs (FcgRI, FcgRIIa, FcgRIIb and FcgRIIIa) were quantiﬁed.
Associations between autologous nAb titers with markers of
disease progression (namely CD4 T-cell counts and viral loads)
were investigated.Results
Study participants
There were eight participants in this study, seven female and
one male. Table 1 depicts the clinical proﬁles of the participants
for this retrospective study. All participants were of African
descent. All participants were antiretroviral treatment naı¨ve for
a median of 21 months. The median age was 31 years (range:
22–59 years). The median CD4 T-cell count at study entry was
578 cells/ml (range: 503–936 cells/ml) and at study exit was
369 cells/ml (range: 218–881 cells/ml). The median viral load at
study entry was 6140 copies/ml (range: 2210–14,360 copies/ml)
and at study exit was 14,750 (range: 2440–345,000 copies/ml).
The mean CD4 T-cell decline rate was 7 cells/ml per month
(standard error 1.50 cells/ml). Since data on the length of time that
participants were infected was unavailable, sequence analysis
was performed by using the Bayesian evolutionary analysis by
sampling trees (BEAST) to estimate the approximate time of
infection in both groups of participants. Participants were esti-
mated to be infected for a mean period of 5.1 years (range: 9
months15 years).
Autologous neutralizing antibody responses become potent over time
in chronic infection
To better understand autologous neutralization during chronic
infection we tested the participants’ plasma against their plasma-
derived Envs using a pseudovirus-based assay (see Fig. 1A). The
titers represented on Fig. 1(B) were the average nAb IC50 titers of
two or three Envs per participant.
NAb IC50 titers for the study entry and study exit Envs differed
when the study entry and study exit plasma antibody responses
were compared. As shown in Fig. 1(B), there were signiﬁcant
differences when the study entry Envs were tested against the
study exit plasma (median nAb IC50 of 1,178; range: 610–2,286)
compared to the contemporaneous responses at study entry
(median nAb IC50 of 429; range: 119–628; p¼0.002) and studyCD4 T-cell count
study entry (cells/ml)
CD4 T-cell count
study exit (cells/ml)
CD4 T-cell decline rate
(cells/ml/ per month)
649 268 10
680 322 7
936 575 7
561 437 4
595 416 7
503 297 3
547 218 8
545 881 9
Fig. 1. (A) Schematic illustrating the autologous neutralizing antibody challenge assays in all participants over a median of 21 months from study entry to study exit. The
average nAb IC50 titers for study entry and exit Envs used in the assays are shown. The study entry Envs were tested against nAbs from the study entry (contemporaneous)
and study exit plasma samples. Likewise the study exit Envs were tested against nAbs from the study entry and study exit (contemporaneous) plasma samples.
Fig. 1(B) depicts the autologous nAb IC50 titers in study participant entry and exit plasma samples for all participants. Fig. 1(C) and (D) shows the CD4 T-cell decline rate
and the log viral load changes over time respectively. p-Values o0.05 were considered signiﬁcant. p Value was calculated using the two-tailed Mann-Whitney non-
parametric test overall. All the p values (po0.0125) remained statistically signiﬁcant after Bonferroni adjustment for multiple comparisons.
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were no correlations between the rates of CD4 T-cell decline or
viral loads with for the nAb IC50 titers of study entry Envs against
the study exit plasma or between contemporaneous nAb IC50
titers at study entry or study exit- Fig. 1(C) and (D).
Autologous neutralization titers correlated with the length of the
hypervariable regions V1–V2
Previous studies have shown an inverse association between
neutralizing antibody titers and length of variable loops (V1–V2)
and numbers of potential N-linked glycosylation sites (PNGs)(Chackerian et al., 1997; Gray et al., 2007; Pinter et al., 2004;
Rong et al., 2007; Sagar et al., 2006). To better understand the
relationship between genotypic characteristics and neutralization
sensitivity, the average amino acid length of the hypervariable
loops of Env and PNGs were correlated to average autologous nAb
IC50 titers (Fig. 2). Signiﬁcant inverse correlation was found
between the lengths of V1–V2 and nAb IC50 titers (r¼0.80;
p¼0.02) for the entry viruses tested against the study exit plasma.
There was a trend towards C2-V5 length correlation with nAb
IC50 titers (r¼0.67; p¼0.08) and no signiﬁcant correlations for
V1–V5 (r¼0.52; p¼0.2). The same analysis was extended for nAb
IC50 titers and the numbers of potential N-linked glycosylation
Fig. 2. Correlation between the amino acid length of (A) V1–V5, (B) V1–V2 and (C) C2–V5 of Env and autologous neutralization titers (nAb IC50 titer) when study entry
viruses were tested against study exit plasma samples. The Spearman r-coefﬁcient and p-values are shown and a correlation was considered signiﬁcant when po0.05.
Table 2
HIV-1 Env pseudovirus panel of subtype C, B and A reference strains.
HIV isolate Viral
subtype
Tiered
category
Reference
MW965.25 C 1A NIH ARRRP#
ZM197 M.PB7 C 1B (Li et al., 2006)
ConC C 2 (Kothe et al., 2006)
DU156.12 C 2 (Li et al., 2006)
DU172.17 C 2 (Li et al., 2006)
ZM214 M.PL15 C 2 (Li et al., 2006)
CAP45.G3 C 2 (Li et al., 2006)
CAP239.G3 C 2 (Gray et al., 2007)
SF162.LS B 1A (Stamatatos and Cheng-Mayer, 1998)
6535.3 B 1B (Li et al., 2005)
AC10.0.29 B 2 (Li et al., 2005)
WITO 4160.33 B 2 (Li et al., 2005)
TRO.11 B 2 (Li et al., 2005)
QHO692.42 B 2 (Li et al., 2005)
PVO.4 B 3 (Li et al., 2005)
Q23ENV17 A 2 (Blish et al., 2007)
Q842ENVd12 A 2 (Blish et al., 2007)
Q168ENVa2 A 2 (Blish et al., 2007)
Q461ENVe2 A 2 (Blish et al., 2007)
Q769ENVd22 A 2 (Blish et al., 2007)
NIH ARRRP#—National Institutes of Health AIDS Research and Reference Reagent
Program.
D. Archary et al. / Virology 433 (2012) 410–420 413sites (PNGs) in the various hypervariable loops and there were no
signiﬁcant correlations observed.
Neutralization breadth scores and potency scores indicate subtype-
speciﬁc responses in chronic infection
To assess neutralization breadth in this chronic infection cohort,
we investigated changes in plasma neutralization activity over
a median of 21 months. Fig. 3 depicts the proﬁle of plasma
neutralizing activity against a panel of heterologous Envs for the
eight study participants at study entry and study exit. A total of 20
reference pseudoviruses from subtype A, B and C (as depicted in
Table 2) were used to determine breadth and potency scores of
neutralization according to the criteria previously described (Blish
et al., 2008). Results are presented as a breadth score per subtype
virus panel, and a total breadth score including all the subtype A, B
and C viruses. Results are presented as potency scores per subtype,
and total potency scores including all the subtype A, B and C viruses.
There was a wide range of variation in neutralization titers
with most of the sera from the participants displaying preferential
heterologous activity against the subtype C panel (Fig. 3). Sig-
niﬁcantly higher breadth scores were observed against subtype C
viruses (median: 3; range: 1–7) compared to subtypes A (median:
2; range: 0–4; p¼0.03) or B (median: 2; range: 0–6;
p¼0.01)—Fig. 3. Likewise, signiﬁcantly higher potency scores
were observed against subtype C viruses (median: 7.6; range:0–152.1) compared to subtypes A (median: 4; range: 0–13.8;
p¼0.03) or B (median: 3.9; range: 0–26.9; p¼0.05). Three of the
participants (SK200, SK221 and SK233) showed a consistent
increase of neutralization breadth scores and potency scores from
study entry to study exit for subtypes C, B and A respectively
translating into overall increase in total breadth and potency
scores as well. Analysis of these participants indicated signiﬁ-
cantly higher viral load at study entry compared to study exit
(p¼0.04); suggesting that increasing breadth may be a result of
higher antigenic stimulation.
SK200 displayed the highest breadth scores and also had potent
nAb IC50 scores (Fig. 3) to six of the eight subtype C viruses tested
including ﬁve of six tier 2 viruses. SK200 had a total neutralization
breadth score of 16 (range: 2–16) and the overall potency score was
177.1 (range: 3–177.1) at study exit. SK200 neutralized subtype
C – tier 2 viruses – CAP45.G3 and CAP239.G3 at study entry and exit
plasmas, and CAP45.G3 in particular, was neutralized at nAb IC50
titers of 42000 (range: 45–5,326). SK200 also displayed the highest
titers 41000 at study entry (range: 45–1316) and study exit (range:
45–1829) to a subtype A tier 1 virus – Q23ENV17.
CD4 T-cell count and viral load are not correlated with neutralization
breadth
A number of studies have shown an inverse relationship between
neutralization breadth and CD4 T-cell counts and a positive correla-
tion with viral loads (Euler et al., 2010; Gray et al., 2011; Piantadosi
et al., 2009; Sather et al., 2009). To better understand the relation-
ship between neutralization and clinical disease markers in this
subtype C chronic cohort, we investigated the association of CD4
T-cell counts and viral loads with neutralization breadth or potency
over a median of 21 months. However, there were no signiﬁcant
correlations between CD4 T-cell counts or viral loads and total
breadth and potency scores (data not shown). A larger sample size
may have been able to detect signiﬁcant correlations between
breadth or potency and markers of disease progression.
Mapping of potential epitopes targeted by cross-neutralizing
antibodies
The putative targets of neutralization in participants display-
ing the highest breadth scores for neutralization at study exit
(SK200, SK221 and SK233) against the reference panel viruses
were further investigated (using study exit plasma samples).
Single point mutations in V2 (N160A, K165E or L165A) and C3
(N332A) were introduced into CAP45.G3, ConC, Du156.12, TRO.11
and Q23.17 and tested for loss of sensitivity against the three
plasmas.
As depicted in Table 3, 5.6-fold and 4-fold drops in neutraliza-
tion titers (relative to the wild type neutralization titers) were
seen when plasma samples from SK221 and SK233, respectively,
Table 3
Effects of single point mutations on neutralization sensitivity and summary of antibody speciﬁcities.
Plasma sample
identity
Fold effect of mutationa Antibody speciﬁcity
conferring breadth
ConC
N160A
ConC
I165A
ConC
K169E
CAP45
N160A
CAP45
I165A
CAP45.G3
K169E
Du156.12
N332A
Q23.17
N332A
Tro.11
N332A
SK200 study exit 1.1 0.5 0.7 1.0 0.6 1.9 1.2 1.5 0 Unknown
SK221 study
exit
0.4 0.3 1.1 2.0 0.4 5.6 1.4 0.6 4.2 Quaternary, PG9/PG16 like N332
SK233 study
exit
0.1 0 0.6 0.8 0.9 4 0.7 1.2 0 Quaternary PG9/
PG16 like
a Calculated as wild type IC50/mutant IC50 for the plasma. Changes in titer of 43 fold are shown in bold.
Fig. 3. Heterologous responses of participant plasma tested at study entry and study exit against 20 Env pseudoviruses from a standard reference panel including subtypes
C, B and A of tier 1A, 1B, tier 2 and 3 categories over a median of 21 months. The neutralization titer is shown as reciprocal plasma dilution required to inhibit 50% of virus
infectivity when the virus is challenged with the participant’s plasma. The highest titer (41,000) is shown in red, and the lowest in light orange, yellow depicts a titer of
o1:45 that is below detection as shown above.
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This suggested that the broadly neutralizing antibodies in these
two participants targeted the V2 region and that a charge change
from a lysine (K) to glutamic acid (E) at position 169 resulted in a
disruption to the nAb epitope. In addition SK221 plasma also
showed a 4.2 fold drop in neutralization titers to N332A made in
the TRO.11 envelope indicating that the asparagine (N), or
perhaps a potential N-linked glycosylation at this position, was
essential for the antibody activity. Together, these results sug-
gested that SK221 most likely had cross-neutralizing antibodies
that target the V2 and C3 regions on Env. SK200, who displayed
the highest neutralization breadth score, neutralized the wild-
type and mutant viruses equivalently suggesting that this parti-
cular participant may have antibodies directed to other regions of
Env, a proﬁle that warrants further investigation.
HIV-speciﬁc IgG binding titers for p24, gp120 or gp41 in chronic
infection over 21 months
We isolated total immunoglobulins (IgGs) from study partici-
pants at study entry and study exit time points and measured the
speciﬁcity and the binding afﬁnity of IgGs to HIV-1 speciﬁc antigens.
There were no signiﬁcant differences in the median EC50 binding
afﬁnities between study entry and study exit for p24, gp120 or gp41.
Interestingly, at study entry, the median IgG binding afﬁnities for
gp120 (median: 137; range: 11.3–153.0) was signiﬁcantly lower
than for gp41 (median: 96.8; range: 71.9–112.1; p¼0.0002). Binding
afﬁnity for gp120 compared to p24 trended to be higher (median:
154.3; range: 57.9–293.9; p¼0.09)—Fig. 4. These ﬁndings may
suggest that binding IgGs were selectively binding gp41compared
to gp120 during the chronic infection stage. In addition, there were
no signiﬁcant correlations between the CD4 T-cell counts or viralloads at study entry or exit with the EC50 of p24, gp120 or gp41
over the study period.
IgG binding afﬁnities differ for the various FcgR I, IIa, IIb and IIIa
To determine if the binding afﬁnities of the IgGs with various
activating and inhibitory FcgRs were different, we measured and
compared the EC50 binding titers over time between study entry
and study exit time-points, and overall (Fig. 5A). IgG binding for
FcgRI at study entry was signiﬁcantly higher than for FcgRIIIa
(po0.0005). Likewise at study exit, the binding afﬁnity of IgG for
the FcgRI were consistently higher compared with FcgRIIb (po0.05)
and FcgRIIIa (po0.0005). Signiﬁcantly higher binding afﬁnities for
FcgRIIa at study entry were noted when compared to FcgRIIIa at
study entry (po0.05). Likewise at study exit, the binding afﬁnity of
IgG for the FcgRIIa was higher compared to FcgRIIIa (po0.05) in
chronic HIV-1 C disease. Collectively, these results indicated that
there was differential kinetics of binding afﬁnities of the IgG during
chronic infection, which may then impact downstream non-
neutralizing activity through ADCC. Sustained high afﬁnity IgG
binding to FcgRI may be preserved during chronic infection. There
were no signiﬁcant correlations between viral loads or CD4 T-cell
counts with the EC50 IgG binding titers to the various receptors
(FcgR I, IIa, IIb and IIIa)—Fig. 5(B) and (C).Discussion
Neutralizing and binding antibodies may play a role in HIV disease
progression but these parameters have rarely been investigated
concurrently. We therefore undertook this study in individuals
chronically infected with HIV-1 subtype C, the most abundant
p2
4 E
ntr
y
p2
4 E
xit
gp
12
0 E
ntr
y
gp
12
0 E
xit
gp
41
 E
ntr
y
gp
41
 Ex
it
0
100
200
300
400
p=0.0002
EC
50
Fig. 4. (A) IgG EC50 binding titers for gp41, gp120 and p24-speciﬁc antibodies at study entry and exit time points. Panels for Fig. 4(B) and (C) show the correlation of EC50
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D. Archary et al. / Virology 433 (2012) 410–420 415subtype worldwide, to characterize neutralizing and binding antibody
patterns in chronic disease, and to determine whether certain
genotypic env characteristics are associated with autologous or
heterologous nAb responses. Our data indicated that nAbs did not
appear to protect against disease progression, rather, greater type-
speciﬁc neutralization breadth and potency against subtype C Envs
and increasing autologous nAb titers were associated with chronic
disease progression. NAb IC50 titers were correlated with env
genotypic characteristics, including increased amino acid length in
hypervariable regions V1–V2 of gp120.
In this study, nAb potency or breadth did not predict disease
progression rate in individuals with chronic HIV-1 subtype C
infection. However, a number of interesting ﬁndings were appar-
ent. Firstly, high-level neutralizing titers to contemporaneous
autologous virus were not observed in most of the participants.
Instead, we observed signiﬁcantly higher autologous responses
over time (when the study entry viruses were tested against the
study exit plasma) compared to contemporaneous responses,
which suggests that nAb are continuously evolving during chronic
infection. These ﬁndings also argue that an increased nAb titer
per se is not effective at attenuating disease progression butrather is a marker of disease progression. Secondly, autologous
nAb IC50 titers correlated inversely with longer amino acid length
for V1–V2 length indicating that increased length in this domain
may be masking key neutralization epitopes. Indeed, evidence for
V2 dependent epitopes was observed in SK221 and SK233. This
data suggests that V1–V2 of Env may be persistently targeted by
nAb in the chronic infection stage. Alternatively, there may be
other intrinsic genetic differences of env that dictate neutraliza-
tion potency and breadth that need to be further deﬁned. Lastly,
the dynamic nature of IgG binding afﬁnity to various FcgRs and
the selective high afﬁnity binding to HIV-1 gp41 may be indica-
tive of chronic disease progression.
The selective increase in neutralization breadth over time sug-
gests that this parameter could be a marker of disease progression in
chronic subtype C infection (Euler et al., 2010). Neutralization
breadth did not signiﬁcantly correlate with markers of disease
progression (viral loads and CD4 T-cell counts) in this chronic
HIV-1C infection cohort, although the small sample size and short
time-frame may have severely limited our statistical power to
address this issue. Gray et al. (2011) found signiﬁcant correlations
between CD4 T-cell count and viral load with neutralization breadth
Fig. 5. (A) EC50 binding titers of IgGs for FcgRI, FcgRIIa, FcgRIIb and FcgRIIIa at study entry and exit time points. Intra- or inter-group comparisons were statistically
different i.e. po 0.05. Fig. 5(B) and (C). Correlation of CD4 T-cell counts at study entry and study exit with FcgRI, FcgRIIa, FcgRIIb and FcgRIIIa (EC50) are shown. Only p-
values o0.05 are shown.
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et al., 2011). These observations suggest that higher antigenic
stimulation may dictate the breadth of heterologous antibody
responses (Doria-Rose et al., 2010; Fraser et al., 2007; Goujard
et al., 2006; Mellors et al., 1997; Piantadosi et al., 2009; Sather
et al., 2009). Although increased neutralization antibody breadth
may not be protective against disease progression, they may be
effective against super-infection as has been suggested by some
studies (Smith et al., 2006 and Deeks et al., 2006), although
conﬂicting data exists (Blish et al., 2008). Together, these studies
have implications for HIV vaccine design, as vaccine immunogens
may need to be given over long periods of time to stimulate the B
cell response, and to facilitate afﬁnity maturation which appears to
be necessary for antibodies to acquire cross-neutralizing activity
(Pancera et al., 2010). For the participants who displayed potent
cross-neutralizing antibody responses, their nAbs likely targeted
quaternary V2 epitopes similar to PG9/PG16-like antibodies (Moore
et al., 2011). In addition, nAbs that targeted the N332 glycan in C3suggest that the asparagine in that position is essential for neutra-
lization activity. In subtype C infection, the V1–V2 and C3 regions
are the immunodominant regions commonly targeted by AnAbs
particularly during the early stage of infection (Lynch et al., 2011;
Moore et al., 2008, 2009; Rong et al., 2009). Our results indicate the
V1–V2 and C3 regions remain immunodominant and the focus of
the nAb response resulting in broadly cross-neutralizing antibodies
even during chronic progressive HIV-1 disease.
A decline of p24 antibody titers as disease progresses has
previously been reported (Allain et al., 1987; Binley et al., 1997;
Forster et al., 1987; Lange et al., 1986), and it is therefore not
surprising that the p24-speciﬁc IgGs may lose their afﬁnity over
time. Chargelegue and colleagues found that low p24 IgG afﬁnity
correlated with HIV-1 disease progression (Chargelegue et al., 1995).
Low afﬁnity IgG HIV-1 speciﬁc binding antibodies may be indicative
of chronic disease progression. It is plausible that a relative decrease
in the binding afﬁnity for activating FcgRIIa and FcgRIIIa may be
consequent to changes in the Fc portion of the IgGs which do not
D. Archary et al. / Virology 433 (2012) 410–420 417affect FcgRI binding. Polymorphisms in the FcgRIIa (Forthal and
Moog, 2009), and the extent of glycosylation of the antibodies
(Forthal et al., 2010) affect binding afﬁnity. Additionally, a decrease
in binding afﬁnity of FcgRIIa was associated with dysfunction in the
expression of these receptors on the cells of the innate immune
system (Dugast et al., 2011). Dugast and colleagues purport that HIV
infection is associated with a number of changes in FcR expression
on phagocytic cells that are associated with changes in their ability
to respond to antibody-opsonized targets, leading to a failure in viral
clearance in chronic infection (Dugast et al., 2011). We found a
consistently high afﬁnity binding of IgG to FcgRI over time which
may suggest that the non-neutralizing pathway augmenting effector
cell activity may be maintained during the chronic infection stage.
However, in the absence of a functional assay, our data do not
provide deﬁnitive answers on whether high afﬁnity binding IgG to
FcgRI is biologically signiﬁcant in chronic infection and what the
proﬁles of the various FcgR–IgG binding were during the initial
HIV-1 infection stages.
Some limitations of our study are worth noting. Firstly, we
only tested a limited number of viral clones from each patient,
and therefore may have biased the results of the study to the
cloned variants only. Secondly, we do not know the exact time of
infection for the study participants and relied on short-term
median (21 months) follow-up immunological data, which may
be an unrepresentative snap-shot of the entire natural history of
disease progression for these participants. Thirdly, the small
sample size meant that our study was underpowered to reach
deﬁnitive conclusions regarding the signiﬁcance of breadth of
neutralization and autologous responses in attenuating disease.
Fourthly, we used binding afﬁnity assays as an indication of the
strength of afﬁnity of the Fc portion of IgG to the FcgRs which
may affect downstream in vivo effector cell activity. Lastly, the
dynamic nature of IgG binding afﬁnity to various FcgRs and the
selective high afﬁnity binding to HIV-1 gp41 may be indicative of
differences and evolution of the antibody mediated innate anti-
viral immune response in progressive HIV-1 subtype C infection,
although this will require additional functional assays to prove.
Despite these caveats, the ﬁndings suggest that an ongoing de
novo nAb response does not directly protect against disease pro-
gression during chronic HIV-1 subtype C infection, corroborating
data from previous studies. Our results are also consistent with data
from non-human primate studies showing that high titer neutraliz-
ing antibody titers are not found in sooty mangabeys (Li et al., 2010)
suggesting that autologous nAb are not part of the protection
against disease progression in HIV and SIV infections. Furthermore,
overall nAb breadth increased over time in most subjects, regardless
of their disease status. The mechanism by which nAb breadth
increased in these subjects is of interest. Thus, it will be important
to determine which Env epitopes in chronically infected individuals
elicit broadly neutralizing antibodies and whether these provide any
clinical beneﬁt to the patient. In addition, animal studies suggest
that anti-HIV antibodies can protect against HIV-1 infection (Burton
et al., 2011; Hessell et al., 2009, 2010) and vaccine-induced V1–V2
binding antibodies may be able to prevent infection (Haynes et al.,
2012). Future studies will need to address whether neutralizing and
binding antibodies from HIV infected individuals may be used to
halt or reduce HIV acquisition.Materials and methods
Participants
Participant samples were retrospectively identiﬁed from the
Sinikithemba cohort, which is a prospective natural history study
of HIV-1 infected individuals based at McCord Hospital, Durban,South Africa as previously reported (Kiepiela et al., 2004). Human
subjects for this study were eight chronically-infected individuals
with heterogenous rates of clinical disease progression as pre-
viously described (Archary et al., 2010). The median period of
follow-up overall was 21 months. Ethical approval for this study
was obtained from the University of KwaZulu-Natal Biomedical
Research Ethics Committee and all participants gave written
informed consent to participate in the study.
Sample collection, CD4 T-cell counts and plasma viral load
CD4 T-cell counts were performed at three-month intervals
whereas viral loads were done at six-month intervals as pre-
viously described (Archary et al., 2010). Blood was drawn from
each subject into EDTA tubes and plasma was separated by
centrifugation and stored at 80 1C until use. Viral load was
measured using the Amplicor Version 1.5 assay (Roche, Alameda
CA, USA). CD4 T-cell counts were enumerated by Trucount
technology on a four color FACSCalibur ﬂow cytometer (Becton
Dickinson, Franklin Lakes, New Jersey, USA).
Envelope clones
Brieﬂy, single genome PCR ampliﬁcation derived env ampli-
cons were directionally T/A cloned into the CMV-driven expres-
sion plasmid pcDNA3.1-V5 HisTOPO-TA and screened for
biological function as pseudoviruses following co-transfection
with an env-deﬁcient subtype B proviral plasmid (SG3DEnv) into
293 T cells as described previously (Derdeyn et al., 2004; Haaland
et al., 2009). A total of 20 standard reference envelope clones
were obtained from the NIH AIDS Research and Reference Reagent
Program and used in the heterologous neutralization assays.
These included ﬁve subtype A, seven subtype B and eight subtype
C envelope pseudoviruses as depicted in Table 2. Tier 1, 2 and
3 viruses were stratiﬁed previously based on a continuum of
patterns of neutralization sensitivity—with tier 1A being the most
sensitive, tier 1B above average, tier 2 displaying moderate to low
sensitivity and tier 3 displaying the lowest sensitivity to neutra-
lization (Seaman et al., 2010). The ConC plasmid based on the
consensus of all the HIV-1 subtype C sequences from the Los
Alamos database by 2001 was obtained from Dr Feng Gao (Kothe
et al., 2006). The envelope plasmids containing single point
mutations are described by Gray et al. (2011).
Neutralization assays
Patient plasma samples were evaluated for nAb activity
against virions pseudotyped with autologous patient-derived
viral Envs using a single reporter assay as described previously
(Derdeyn et al., 2004; Gray et al., 2007; Li et al., 2005, 2006; Wei
et al., 2003). Fig. 1(A) illustrates the schema used for autologous
neutralizing antibody challenge assays where the study entry and
exits Envs were tested for neutralization using the study entry
and study exit plasma nAb samples for eight study participants.
A total of 37 autologous Envs were tested against their study
entry plasma and study exit plasma (range: 2–6 env clones per
participant). Neutralization was measured as a reduction in
luciferase gene expression after a single round of infection of
TZM-bl cells (NIH AIDS Research and Reference Reagent Program).
Two thousand infectious units of each pseudovirus was combined
with ﬁve-fold dilutions of heat-inactivated participant plasma
and incubated for 1 h at 37 1C as previously described (Rong et al.,
2009). Subsequently, the virus and antibody reaction was added
to the plated TZM-bl cells, and left to incubate at 37 1C for 48 h.
The cells were then lysed and the luciferase activity was deter-
mined using a BioTek Synergy HT (BioTek, USA). The background
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test wells. The percentage of infectivity was calculated by divid-
ing the number of luciferase units at each plasma dilution by the
value in the well containing no test plasma. The dilution that
yielded 50% inhibitory activity against the virus, known as the
nAb IC50 titer was determined on Microsoft Excel. Each experi-
ment was performed in duplicate and independently at least
twice for replicability. The nAb IC50 titer was calculated as the
reciprocal plasma dilution causing a 50% reduction of relative
light units (IC50). Heterologous assays were done as previously
reported (Monteﬁori, 2004). Brieﬂy, positive neutralization was
scored as an IC50 titer above 1:45. The nAb breadth and potency
was determined as a score based on the median IC50 titer for each
virus as reported by Blish et al. (2008).
Plasma IgG isolation
Total IgGs were puriﬁed from the participant’s plasma samples
using the Melon Gel (Thermo Scientiﬁc, Surrey, United Kingdom)
method according to the manufacturer’s instructions. Brieﬂy,
500 ml of a 1:10 dilution of plasma to buffer was added to the
column. The tubes were rotated for 5 min in order to ensure
maximum capture of the IgGs and were then spun down for 1 min
at 5000x g to elute the IgGs. IgG concentrations were measured
on the NanoDrop 2000 Spectrophotometer (Thermo Scientiﬁc,
Surrey, United Kingdom) and stored at 4 1C for downstream ELISA
assays.
Gp120, gp41, and p24 Binding ELISAs
Binding afﬁnities of the bulk population of IgGs puriﬁed from
plasma were measured for the various HIV-1 speciﬁc antigens –
gp120, gp41 and p24. ELISA plates were coated with 80 ml/well of
250 ng/ml gp120 (Immune Technology, New Jersey, USA) or gp41
(Immune Technology, New Jersey, USA) or p24 (Immune Tech-
nology, New Jersey, USA) and then incubated O/N at 4 1C. The
plates were washed three times with PBS Tween 0.05% and
blocked with 5% PBS–BSA for 2 h at RT (100 ml/well). IgGs isolated
previously were diluted in PBS and added to respective wells
according to a ten times serial dilution to respective wells and
incubated for 2 h at RT. The plates were washed three times with
0.05% PBS Tween. 100 ml anti-human IgG antibody, Fab fragment,
peroxidase labeled was added to each well (KPL Protein Research
Products, Maryland, USA) and left for 1 h at RT (1:500 diluted-per
plate: 20 ml HRP in 10 ml PBS) and covered in tinfoil. The plate
was washed 3 times with 0.05% PBS–Tween. One OPD tablet was
added to 11 ml of phosphate citrate bufferþ4.4 ml hydrogen
peroxide (H2O2); and 50 ml/well were added. The reaction was
stopped by adding 50 ml 2.5 N H2SO4 per well. The plate was read
at 490 nm on a microplate reader and the data analyzed using
GraphPad Prism 5 software.
FcGamma (g) receptor binding ELISAs
Binding afﬁnities of the bulk population of IgGs puriﬁed from
plasma were measured for the various activating – FcgRI, FcgRIIa
and FcgRIIIa – (R & D Systems, Minneapolis, USA) and inhibitory
receptors – FcgRIIb.
Each ELISA plate (Ni-NTA HisSorbTM Plate Qiagen, Dusseldorf,
Germany) was coated with 100 ml/well of diluted FcgR (FcgRI,
FcgRIIa, FcgRIIb, and FcgRIIIa) at a concentration of 5 mg/ml using
PBS. One receptor type per plate was added and incu-
bated overnight (O/N) at room temperature (RT). The plate was
washed three times with PBS–Tween (0.05%) and blocked with
250 ml/well 5% PBS–Bovine Serum Albumin (BSA) (Sigma-Aldrich,
St Louis, USA) and then incubated for 1 h at RT. The plate waswashed three times with 0.05% PBS–Tween. 100 ml/well of anti-
bodies were added (the IgGs derived from the test plasma were
diluted serially starting at 100 mg/ml diluted down to 1.6 mg/ml) to
the respective wells and was left to incubate for 1 h at RT. The
plate was washed three times with 0.05% PBS–Tween. 100 ml per
well of anti-human IgG antibody, Fab fragment, peroxidase
labeled was added (KPL Protein Research Products, Maryland,
USA). 20 ml of HRP Fab (1 mg/ml) was added to 10 ml PBS 1X for
one plate. The plate was incubated for 1 h at RT and covered to
protect it from light. The plate was washed three times with 0.05%
PBS–Tween. The color was resolved with 100 ml/well of O-
phenylenediamine (OPD) (Sigma-Aldrich, St Louis, USA) – one
OPD tablet was added to 11 ml of StrepHRP substrate), the
reactions were stopped by adding 100 ml/well of 2.5 N sulfuric
acid (Sigma-Aldrich, St Louis, USA). The plate was read at 490 nm
using the Tecan Sunrise 16039400 plate reader (Tecan Group,
Switzerland). The optical density data was exported to Microsoft
Excel worksheet to calculate the 50% effective concentration
(EC50) of each batch of total IgGs needed to bind HIV-speciﬁc
gp41, gp120 and p24 antibodies and various FcgR using an ELISA-
based assay. EC50 (mg/ml) corresponds to the concentration of
antibody needed to achieve half of the maximal binding to FcgR.
The EC50 binding titer of the IgGs was used as a surrogate
indicator of how strongly or poorly the IgGs’ Fc portion may bind
to the FcgR to recruit effector cells like phagocytic (macrophages)
or non-phagocytic (natural killer cells) cells to initiate either
ADCVI or ADCC activity. Essentially, the higher the EC50 the more
antibody is needed for antiviral activity like ADCC or ADCVI to
occur, the lower the afﬁnity of antibody binding to the respective
target cells bearing the antigens e.g. the FcgRs to antibodies to
initiate effector functions.
Statistical analyses
Comparisons of different parameters including nAb IC50 titers
for both the autologous and heterologous responses, and binding
afﬁnities of the various HIV-speciﬁc antigens and FcgRs to IgGs was
performed. Intra-group comparisons between study entry and study
exit time-points were done using the Mann-Whitney U test and the
Spearman rank correlation test. ANOVA was used to compare three
or more groups and the Dunn’s post-test was used to perform
pairwise comparisons. A general linear model was used to estimate
the rate of change in viral load and CD4 T-cell count over time. Viral
load was log-transformed to ensure normality. All reported p values
are two-sided and are considered signiﬁcant if less than 0.05. The
statistical analysis was performed using GraphPad Prism 5 and SAS
version 9.3 (SAS Institute Inc., Cary).Acknowledgments
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